| Not Yet Recruiting | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) NCT07460765 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377 | EpiBiologics | Phase 1 |
| Not Yet Recruiting | Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial NCT07491783 | Sichuan Enray Pharmaceutical Sciences Company | Phase 2 |
| Recruiting | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors NCT07035249 | West China Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis NCT07246759 | OncoHost Ltd. | — |
| Recruiting | Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors NCT07081984 | Therorna | Phase 1 |
| Recruiting | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149 | Normunity AccelCo, Inc. | Phase 1 |
| Recruiting | A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 | West China Hospital | Phase 1 |
| Recruiting | High-Resolution PET-CT Imaging for Surgical Margin Visualization NCT06915454 | Vanderbilt-Ingram Cancer Center | N/A |
| Recruiting | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors NCT07085091 | ALX Oncology Inc. | Phase 1 |
| Recruiting | A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurren NCT07136545 | Taipei Veterans General Hospital, Taiwan | Phase 1 / Phase 2 |
| Not Yet Recruiting | PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immun NCT07090707 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resect NCT07010120 | West China Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC NCT07040072 | Beijing Tongren Hospital | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer NCT06736379 | VLP Therapeutics | Phase 1 |
| Recruiting | Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer NCT06819228 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Recruiting | Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma NCT06673693 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172 | Epkin | Phase 1 |
| Not Yet Recruiting | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Cur NCT06719479 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 2 / Phase 3 |
| Recruiting | A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted NCT06741982 | West China Hospital | Phase 1 |
| Active Not Recruiting | Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC- NCT07267286 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors NCT06657222 | Tubulis GmbH | Phase 1 / Phase 2 |
| Recruiting | Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC NCT06693323 | University of California, Irvine | Phase 2 |
| Completed | Radiomics Model for Assessing Lymph Node Status in cN0 Patients withHNSCC NCT06757530 | First Affiliated Hospital of Chongqing Medical University | — |
| Recruiting | Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC NCT06755762 | Chang Gung Memorial Hospital | — |
| Recruiting | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962 | Radiopharm Theranostics, Ltd | EARLY_Phase 1 |
| Recruiting | Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors NCT06190275 | Grit Biotechnology | N/A |
| Not Yet Recruiting | Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ H NCT06366945 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors NCT06259552 | SparX Biotech(Jiangsu) Co., Ltd. | Phase 1 |
| Recruiting | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma NCT06016920 | Nykode Therapeutics ASA | Phase 1 / Phase 2 |
| Recruiting | A Study of YL202 in Selected Patients With Advanced Solid Tumors NCT06107686 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 |
| Active Not Recruiting | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carci NCT05980000 | Washington University School of Medicine | Phase 2 |
| Recruiting | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types NCT05877430 | CJ Bioscience, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid T NCT05902520 | AgonOx, Inc. | Phase 1 |
| Terminated | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC NCT05814666 | Flamingo Therapeutics NV | Phase 2 |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Completed | 10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma NCT06366906 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvan NCT05980702 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Unknown | MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer NCT05831917 | Sichuan Cancer Hospital and Research Institute | N/A |
| Unknown | The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma NCT05831930 | Sichuan Cancer Hospital and Research Institute | EARLY_Phase 1 |
| Recruiting | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immun NCT05980715 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combinat NCT05581004 | Genentech, Inc. | Phase 1 |
| Withdrawn | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) NCT04831450 | University of Miami | Phase 2 |
| Completed | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carci NCT04997902 | Kura Oncology, Inc. | Phase 1 / Phase 2 |
| Recruiting | Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carc NCT05192655 | Charite University, Berlin, Germany | — |
| Terminated | Intratumoral Microdosing of Motolimod in HNSCC NCT04272333 | Presage Biosciences | EARLY_Phase 1 |
| Unknown | Immunological Function After Radiation With Either Proton or Photon Therapy NCT06016699 | University Medical Center Groningen | — |
| Completed | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With R NCT04811027 | Immutep S.A.S. | Phase 2 |
| Terminated | Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial) NCT04169074 | University of Arizona | Phase 2 |
| Recruiting | Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy NCT05337631 | University Hospital Freiburg | — |
| Unknown | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squ NCT04861467 | Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiothe NCT04892849 | University of Erlangen-Nürnberg Medical School | — |
| Active Not Recruiting | Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC NCT04340258 | University of Cincinnati | Phase 1 / Phase 2 |
| Recruiting | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer NCT04722523 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation NCT04141449 | Brigham and Women's Hospital | Phase 2 |
| Completed | Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) NCT04606940 | University Health Network, Toronto | — |
| Recruiting | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous NCT04370587 | ImmVira Pharma Co. Ltd | Phase 1 / Phase 2 |
| Recruiting | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies NCT04114136 | Dan Zandberg | Phase 2 |
| Unknown | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors NCT05602792 | ImmVira Pharma Co. Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies NCT04354246 | Compugen Ltd | Phase 1 |
| Completed | Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC NCT04042935 | University of Colorado, Denver | Phase 1 |
| Completed | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors NCT04157985 | Dan Zandberg | Phase 3 |
| Completed | De-Escalation Therapy for Human Papillomavirus Negative Disease NCT03944915 | University of Chicago | Phase 2 |
| Active Not Recruiting | Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN NCT03726775 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 2 |
| Unknown | Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With NCT04279509 | National University Hospital, Singapore | N/A |
| Completed | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response t NCT03719690 | Kura Oncology, Inc. | Phase 2 |
| Completed | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients W NCT03625323 | Immutep S.A.S. | Phase 2 |
| Terminated | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations NCT03740100 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Ne NCT03480672 | University of Leipzig | Phase 2 |
| Recruiting | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors NCT03526835 | Merus B.V. | Phase 1 / Phase 2 |
| Unknown | Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma NCT03652142 | Attikon Hospital | — |
| Unknown | WGA in Platinum-refractory HNSCC Underwent Nivolumab NCT03917537 | Chang Gung Memorial Hospital | — |
| Completed | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell NCT03422536 | University of Arizona | Phase 2 |
| Completed | Dose-Effect Relation of Salivary Gland Irradiation NCT03367780 | The Netherlands Cancer Institute | — |
| Unknown | A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurre NCT03356587 | Seoul National University Hospital | Phase 2 |
| Active Not Recruiting | Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) NCT02999087 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 3 |
| Completed | Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esopha NCT03292250 | Seoul National University Hospital | Phase 2 |
| Completed | Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma NCT06446570 | Seoul National University Hospital | Phase 2 |
| Completed | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer NCT03107182 | University of Chicago | Phase 2 |
| Completed | Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell NCT03182959 | University of Arizona | EARLY_Phase 1 |
| Completed | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinom NCT03082534 | University of California, San Diego | Phase 2 |
| Active Not Recruiting | Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protonthe NCT02998385 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 3 |
| Unknown | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies NCT02433626 | Critical Outcome Technologies Inc. | Phase 1 |
| Completed | Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemo NCT02216617 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 1 |
| Unknown | Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC NCT02216916 | Yonsei University | Phase 2 |
| Completed | Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-e NCT00609284 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 3 |